Debra T. Chao

5.2k citations

28 papers · 4.3k indexed · 3 hit papers · h-index 18

Co-authors: Stanley J. Korsmeyer Jialing Xiang Xiaoming Yin S J Korsmeyer Kai Wang Curt Milliman Lynn S. White Lawrence Boise
Topics: Monoclonal and Polyclonal Antibodies Research (11 papers)Immune Cell Function and Interaction (6 papers)Immunotherapy and Immune Responses (6 papers)
Cited by: Immunology Molecular Biology Oncology
Journals: Proceedings of the National Academy of Sciences The Journal of Experimental Medicine Journal of Clinical Oncology
Partner nations: United States Netherlands Germany

In The Last Decade

Debra T. Chao

28 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

BCL-2 FAMILY: Regulators of Cell Death

1998 1.5k citations Debra T. Chao, Stanley J. Korsmeyer Annual Review of Immunology profile →
BAX-induced cell death may not require interleukin 1β-converting enzyme-like proteases

1996 805 citations Debra T. Chao, Stanley J. Korsmeyer et al. profile →
BID: a novel BH3 domain-only death agonist.

1996 779 citations Kai Wang, Xiaoming Yin et al. Genes & Development profile →

Peers

Countries citing papers authored by Debra T. Chao

Since Specialization

Citations

This map shows the geographic impact of Debra T. Chao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra T. Chao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra T. Chao more than expected).

Fields of papers citing papers by Debra T. Chao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra T. Chao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra T. Chao. The network helps show where Debra T. Chao may publish in the future.

Co-authorship network of co-authors of Debra T. Chao

This figure shows the co-authorship network connecting the top 25 collaborators of Debra T. Chao. A scholar is included among the top collaborators of Debra T. Chao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra T. Chao. Debra T. Chao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	VISTA is an activating receptor in human monocytes 2021 ·The Journal of Experimental Medicine ·(unknown),Laura E. Smith,Zoltán Dezső,Xu Shi,Enrico L. DiGiammarino,(unknown),Sunantha Sethuraman,(unknown),(unknown),(unknown),(unknown),Kathleen A. McGuire,Wei Liu,Namjin Chung,Debra T. Chao,Shiming Ye,Gabriel R. Starbeck-Miller	25
2	Epitope and Fc-Mediated Cross-linking, but Not High Affinity, Are Critical for Antitumor Activity of CD137 Agonist Antibody with Reduced Liver Toxicity 2020 ·Molecular Cancer Therapeutics ·(unknown),(unknown),Archana Thakur,Melvin Fox,(unknown),Enrico L. DiGiammarino,Li Zhou,Mien Sho,Belinda Cairns,(unknown),(unknown),Josue Samayoa,C.M. Forsyth,David B. Powers,Debra T. Chao,Diane Hollenbaugh,Hamsell M. Alvarez,Yoshiko Akamatsu	30
3	A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity 2019 ·Cancer Immunology Research ·Shiming Ye,(unknown),Nicole A. Belmar,(unknown),(unknown),Mien Sho,Yoshiko Akamatsu,Han Kim,(unknown),(unknown),Marc Lake,Danying Song,John E. Harlan,(unknown),(unknown),Alan F. Wahl,Patricia Culp,Diane Hollenbaugh,Debra T. Chao	40
4	LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates 2018 ·Cancer Research ·James W. Purcell,(unknown),Jonathan A. Hickson,Melvin Fox,Mien Sho,Lisa Durkin,Tamar Uziel,Rick Powers,Kelly Foster,Thomas McGonigal,(unknown),Josue Samayoa,Dong Zhang,Joann P. Palma,(unknown),Diane Hollenbaugh,Kurt Gish,Susan E. Morgan-Lappe,Eric D. Hsi,Debra T. Chao	136
5	Enavatuzumab, a Humanized Anti-TWEAK Receptor Monoclonal Antibody, Exerts Antitumor Activity through Attracting and Activating Innate Immune Effector Cells 2017 ·Journal of Immunology Research ·Shiming Ye,Melvin Fox,Nicole A. Belmar,Mien Sho,Debra T. Chao,(unknown),(unknown),(unknown),(unknown),Gary C. Starling,Patricia Culp	12
6	Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR 2014 ·Frontiers in Immunology ·James W. Purcell,(unknown),(unknown),(unknown),Melvin Fox,Peter Lambert,Debra T. Chao,Mien Sho,Keith E. Wilson,Gary C. Starling,Patricia Culp	12
7	Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways 2014 ·Cancer Immunology Immunotherapy ·Balaji Balasa,(unknown),Nicole A. Belmar,Melvin Fox,Debra T. Chao,Michael Robbins,Gary C. Starling,Audie Rice	123
8	PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis 2013 ·Arthritis Research & Therapy ·Jacky Woo,Michel Vierboom,Hakju Kwon,Debra T. Chao,Shiming Ye,Jianmin Li,(unknown),(unknown),Nicole A. Belmar,(unknown),(unknown),Vladimir Vexler,Bert A. ‘t Hart,Debbie A. Law,Gary C. Starling	15
9	Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb 2012 ·Journal of Cancer Research and Clinical Oncology ·Debra T. Chao,(unknown),(unknown),Mien Sho,Donghee Choi,(unknown),Shiming Ye,Eric D. Hsi,Lisa Durkin,Johnny Yin,Yongke Zhang,Han Kim,Gary C. Starling,Patricia Culp	28
10	Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer 2012 ·Annals of Oncology ·Benjamin Besse,L. Claire Tsao,Debra T. Chao,Ying Fang,Jean‐Charles Soria,Salah Almokadem,Chandra P. Belani	68
11	Antibodies to TWEAK Receptor Inhibit Human Tumor Growth through Dual Mechanisms 2010 ·Clinical Cancer Research ·Patricia Culp,Donghee Choi,Yongke Zhang,Johnny Yin,Pui Seto,Suzanne E. Ybarra,(unknown),Mien Sho,Roxanne Steinle,Melanie Wong,(unknown),Jennifer Grove,(unknown),(unknown),Eric D. Hsi,Debra T. Chao,David B. Powers,Vanitha Ramakrishnan,Robert B. DuBridge	62
12	Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma 2009 ·Molecular Cancer Therapeutics ·Frits van Rhee,Susann Szmania,Myles Dillon,(unknown),Xin Li,(unknown),Tarun K. Garg,Jumei Shi,Amberly Moreno-Bost,(unknown),Balaji Balasa,(unknown),Debra T. Chao,Audie Rice,Fenghuang Zhan,John D. Shaughnessy,Bart Barlogie,Shmuel Yaccoby,Daniel Afar	142
13	Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies 2009 ·Immunological Investigations ·Debra T. Chao,Xiaohong Ma,Olga Li,Hyunjoo Park,Debbie A. Law	25
14	Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model 2009 ·Journal of Neuroimmunology ·Nicole A. Belmar,(unknown),Debra T. Chao,Olga Li,Xiaohong Ma,(unknown),Debbie A. Law,Gary C. Starling	6
15	A function blocking anti-mouse integrin α5β1 antibody inhibits angiogenesis and impedes tumor growth in vivo 2007 ·Journal of Translational Medicine ·Vinay Bhaskar,Dong Zhang,Melvin Fox,Pui Seto,Melanie Wong,Pauline Wales,David B. Powers,Debra T. Chao,Robert B. DuBridge,Vanitha Ramakrishnan	66
16	Paraneoplastic “stiff person syndrome” with metastatic adenocarcinoma and anti-Ri antibodies 2004 ·Neurology ·Dominick J. H. McCabe,Nicholas C. Turner,Debra T. Chao,Alexander Leff,Norman A. Gregson,(unknown),I. Tong Mak,G D Perkin,Anthony H.V. Schapira	32
17	BCL-2 FAMILY: Regulators of Cell Deathbreakdown → 1998 ·Annual Review of Immunology ·Debra T. Chao,Stanley J. Korsmeyer	1452
18	BCL-XL-regulated apoptosis in T cell development 1997 ·International Immunology ·Debra T. Chao	53
19	BID: a novel BH3 domain-only death agonist.breakdown → 1996 ·Genes & Development ·Kai Wang,Xiaoming Yin,Debra T. Chao,Curt Milliman,S J Korsmeyer	779
20	Bcl-XL and Bcl-2 repress a common pathway of cell death. 1995 ·The Journal of Experimental Medicine ·Debra T. Chao,Gerald P. Linette,Lawrence Boise,Lynn S. White,Craig B. Thompson,S J Korsmeyer	355

About Debra T. Chao

Debra T. Chao is a scholar working on Immunology and Allergy, Immunology and Radiology, Nuclear Medicine and Imaging, having authored 28 papers that have together received 4.3k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (11 papers), Immune Cell Function and Interaction (6 papers) and Immunotherapy and Immune Responses (6 papers). The work is most often cited by research in Immunology (1.2k citations), Molecular Biology (2.9k citations) and Oncology (1.1k citations). Debra T. Chao has collaborated with scholars based in United States, Netherlands and Germany. Frequent co-authors include Stanley J. Korsmeyer, Jialing Xiang, Xiaoming Yin, S J Korsmeyer, Kai Wang, Curt Milliman, Lynn S. White, Lawrence Boise, Craig B. Thompson and Gerald P. Linette. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact